Cybin Inc. (CYBN)

USD 6.5

(-1.81%)

Net Income Summary of Cybin Inc.

  • Cybin Inc.'s latest annual net income in 2023 was -78.08 Million CAD , down -95.02% from previous year.
  • Cybin Inc.'s latest quarterly net income in 2024 Q1 was -14.82 Million CAD , up 30.55% from previous quarter.
  • Cybin Inc. reported an annual net income of -40.03 Million CAD in 2022, up 43.94% from previous year.
  • Cybin Inc. reported an annual net income of -71.42 Million CAD in 2021, down -121.68% from previous year.
  • Cybin Inc. reported a quarterly net income of -30.33 Million CAD for 2023 Q3, down -155.09% from previous quarter.
  • Cybin Inc. reported a quarterly net income of -78.08 Million CAD for 2023 FY, down -95.02% from previous quarter.

Annual Net Income Chart of Cybin Inc. (2023 - 2016)

Historical Annual Net Income of Cybin Inc. (2023 - 2016)

Year Net Income Net Income Growth
2023 -78.08 Million CAD -95.02%
2022 -40.03 Million CAD 43.94%
2021 -71.42 Million CAD -121.68%
2020 -32.22 Million CAD -1557.41%
2019 -1.94 Million CAD -1833.87%
2018 -100.52 Thousand CAD 0.0%
2016 -127.21 Thousand CAD 0.0%

Peer Net Income Comparison of Cybin Inc.

Name Net Income Net Income Difference
AIM ImmunoTech Inc. -28.96 Million USD -169.595%
Armata Pharmaceuticals, Inc. -69.04 Million USD -13.086%
Actinium Pharmaceuticals, Inc. -48.81 Million USD -59.941%
Azitra, Inc. -11.28 Million USD -591.967%
Can-Fite BioPharma Ltd. -7.63 Million USD -922.793%
Chromocell Therapeutics Corporation -7.38 Million USD -957.881%
Calidi Biotherapeutics, Inc. -29.21 Million USD -167.251%
CEL-SCI Corporation -32.36 Million USD -141.242%
iBio, Inc. -24.9 Million USD -213.486%
Lineage Cell Therapeutics, Inc. -21.48 Million USD -263.399%
MAIA Biotechnology, Inc. -19.77 Million USD -294.884%
Matinas BioPharma Holdings, Inc. -22.94 Million USD -240.337%
NovaBay Pharmaceuticals, Inc. -9.64 Million USD -709.959%
NanoViricides, Inc. -8.29 Million USD -841.387%
Oragenics, Inc. -20.65 Million USD -278.006%
BiomX Inc. -26.16 Million USD -198.368%
BiomX Inc. -26.16 Million USD -198.368%
Protalix BioTherapeutics, Inc. 8.31 Million USD 1039.365%
Palatin Technologies, Inc. -29.73 Million USD -162.576%
Scorpius Holdings, Inc. -45.21 Million USD -72.678%
Theriva Biologics, Inc. -18.34 Million USD -325.527%